Senior Leadership


Our team is comprised of industry leaders with a common commitment: to translate scientific breakthroughs into meaningful advances in treatment for patients.


President and Chief Executive Officer


Edward M. Kaye, M.D. is our President and CEO, and a member of the Board of Directors. Prior to his appointment as Sarepta’s President and CEO, Dr. Kaye, served as the Company’s Chief Medical Officer from June 2011 to April 2017 and Interim Chief Executive Officer from March 2015 to September 2016. Dr. Kaye also serves as a member of the Board of Directors of Cytokinetics, Inc., a position he has held since May 2016.

Dr. Kaye was Group Vice President of Clinical Development at Genzyme Corporation, a biotechnology company, from April 2007 to June 2011, where he supervised the clinical research in the lysosomal storage disease programs and in the genetic neurological disorders. Prior to this, Dr. Kaye held various roles at Genzyme Corporation since 2001, including Vice President of Medical Affairs for Lysosomal Storage Diseases, Vice President of Clinical Research and Interim Head of PGH Global Medical Affairs. Dr. Kaye earned his B.S. in Biology from Loyola University and earned his M.D. at Loyola University Stritch School of Medicine. He received his Pediatric training at Loyola University Hospital, Child Neurology training at Boston City Hospital, Boston University, and completed his training as a Neurochemical Research Fellow (Geriatric Fellow) at Bedford VA Hospital, Boston University. Dr. Kaye was head of the section of Neurometabolism, Pediatric Neurology at The Floating Hospital for Children (Tufts University) and research fellow in gene therapy at Massachusetts General Hospital until 1996 when he moved to Philadelphia to become Chief of Pediatric Neurology and Director of the Barnett Mitochondrial Laboratory at St. Christopher’s Hospital for Children. In 1998, Dr. Kaye accepted the appointment as Chief of Biochemical Genetics at Children’s Hospital of Philadelphia and Associate Professor of Neurology and Pediatrics at the University Of Pennsylvania School Of Medicine until moving to Genzyme Corporation at the end of 2001.

Dr. Kaye continues as a Neurological Consultant at the Children's Hospital of Boston and is on the editorial boards of a number of journals including Journal of Child Neurology. He also previously served on the board of Annals of Neurology. Dr. Kaye is also on the Medical/Scientific Advisory Boards of the United Leukodystrophy Foundation, Spinal Muscular Atrophy Foundation, CureCMD, CureDuchenne, and the Prize4Life.


Vice President, Global Health Policy and Government Affairs


Diane Berry, Ph.D., has served as our Vice President of Global Health Policy and Government Affairs since December 2011.

Previously Dr. Berry worked for the federal government overseeing and implementing science and technology and public health activities, including CBRN defense efforts, across the legislative and executive branches. Dr. Berry served as a Subcommittee Staff Director and Senior Professional Staff Member for the House Committee on Homeland Security and worked at the Department of Homeland Security in the Office of Health Affairs in leadership roles including Chief Scientist, Director of Threat Characterization and Countermeasures, and Senior Biodefense Advisor. Previously Dr. Berry also served as a Senior Science Advisor at McKenna, Long, and Aldridge. She was a Science & Technology Policy Fellow through the American Association for the Advancement of Science.

Dr. Berry earned her Ph.D. in chemical engineering from Northwestern University and received her B.S. and M.S. in chemical/biochemical engineering from Tufts University.


Senior Vice President, Global Commercial Development


Bo Cumbo joined Sarepta in January 2013 and serves as our Senior Vice President of Global Commercial Development.  

From June 2010 to January 2013, Mr. Cumbo worked at Vertex Pharmaceuticals, a biopharmaceutical company, where he served as Vice President of Sales and Treatment Education for the launch of Incivek, one of the most successful drug launches in the history of U.S. pharmaceuticals.

Prior to working at Vertex, Mr. Cumbo worked for Gilead Sciences, a biopharmaceutical company, for nine years in multiple commercial roles supporting the HIV, HBV and Cardiovascular franchises.  Mr. Cumbo has experience in sales, marketing, national accounts, federal accounts, treatment education and commercial strategy, as well as in building effective teams for successful competitive launches.

Mr. Cumbo started his career at GSK and has over twenty years of pharmaceutical and biotechnology experience, with over ten specialty competitive launches during his career.  Mr. Cumbo received his Bachelor of Science in Medical Technology from Auburn University.


Senior Vice President, General Counsel and Corporate Secretary


Ty Howton has served as our Senior Vice President, General Counsel and Corporate Secretary since November 2012.

From September 2011 to June 2012, Mr. Howton served as the Senior Vice President, Chief Legal Officer and as a member of the executive team at Vertex Pharmaceuticals Incorporated, a publicly-traded biotechnology company, and in this capacity he participated in the general management of the company and oversaw all aspects of the Vertex global legal and compliance departments. Mr. Howton served as Senior Vice President Legal from July 2012 to November 2012. Prior to his appointment as Chief Legal Officer at Vertex, Mr. Howton served as the Chief Compliance Officer from September 2009 to August 2011 and, in this capacity, he was responsible for designing and implementing the Vertex corporate compliance program as well as chairing the company's Corporate Compliance Committee. From 2003 to September 2009, Mr. Howton worked at Genentech, Inc., a biotechnology company, where he served in a number of legal roles before becoming the company's chief healthcare compliance officer in 2006. Prior to joining Genentech in 2003, Mr. Howton was a member of the Sidley Austin LLP corporate healthcare practice where he advised on corporate transactions involving life science companies and provided regulatory counsel.

Mr. Howton holds a B.A. from Yale University and a J.D. from Northwestern University School of Law.


Vice President, Head of Technical Operations


Tim Kelly joined Sarepta in January 2017 as our Head of Technical Operations.

Prior to joining Sarepta Therapeutics, Mr. Kelly was employed by Shire Pharmaceuticals where he rose from Vice President, Global Supply Chain to Head of Technical Operations. His last role at Shire was Senior Vice President and Head of Biologics Operating Unit, where he was responsible for the end-to-end technical operations of all Biologics clinical & commercial products, including seven internal manufacturing sites.

Mr. Kelly also held senior positions at Biogen, Amsterdam, Netherlands, where he directed engineering & management of large scale drug substance green field capacity expansion in Denmark and managed their International multi-product supply chain operations. And at UCB, Belgium, where he managed API & Biologics Technical Operations.

Mr. Kelly received his Bachelor of Science from the USAF Academy, emphasizing in General Engineering studies, and a Master of Science in Business Administration from Troy University. During his service in the USAF he flew F15’s.


Executive Vice President, Chief Financial Officer and Chief Business Officer


Sandy Mahatme has served as our Senior Vice President, Chief Financial Officer since November 2012.

From January 2006 to November 2012, Mr. Mahatme worked at Celgene Corporation, a biopharmaceutical company, where he served in various roles, including Senior Vice President of Corporate Development, Senior Vice President of Finance, Corporate Treasurer and Head of Tax. While at Celgene, Mr. Mahatme built the treasury and tax functions before establishing the Corporate Development Department, focused on strategic, targeted initiatives including commercial development in emerging markets, acquisitions and licensing and global manufacturing expansion. Prior to working at Celgene, Mr. Mahatme worked for Pfizer Inc., a pharmaceutical company, for eight and a half years in senior roles in Business Development and Corporate Tax.

Mr. Mahatme started his career at Ernst & Young LLP where he advised multinational corporations on a broad range of transactions. Mr. Mahatme holds Master of Laws (LL.M.) degrees from Cornell Law School and NYU School of Law and is a member of the New York State Bar Association. Mr. Mahatme is also a board member of Flexion Therapeutics, Inc and Aeglea Biotherapeutics.


Vice President, Medical Affairs and
Patient Advocacy


Dana R. Martin, PharmD, has served as our Vice President of Medical Affairs and Patient Advocacy since August 2015.

Prior to joining Sarepta Therapeutics, Dr. Martin served as Vice President, Global Medical Operations at Synageva BioPharma, working hand-in-hand with the healthcare and patient community to change the paradigm of clinical diagnostic testing for patients at high-risk for Lysosomal Acid Lipase Deficiency (LAL-D). Dr. Martin’s work was instrumental to the identification of LAL-D patients eligible for enrollment in Kanuma™ pivotal clinical trials and to facilitate physician-driven patient diagnosis on an on-going basis, globally. He also worked closely with patient advocacy leaders and patients and families to further disease education of healthcare providers and to advance discussions about newborn screening for the disorder.

Dr. Martin developed his career at Genzyme Corporation where he held various Clinical Research and Medical Affairs positions of increasing responsibility over a 12-year period in the Personalized Genetic Health business unit. During his tenure at Genzyme, he contributed to the clinical development and commercialization of Fabrazyme®, Myozyme® and Lumizyme®.

Dr. Martin holds a BS in Pharmacy and a Doctor of Pharmacy degree from The Massachusetts College of Pharmacy and Health Sciences (MCPHS) in Boston and completed training in Fabry’s disease in the Lysosomal Disorders and Neurogenetics Clinic at Massachusetts General Hospital. He currently serves on the Dean’s Advisory Council for the University of New England’s College of Pharmacy (UNE-COP) and is Adjunct Faculty for Doctor of Pharmacy students from UNE-COP and the University of North Carolina’s Eshelman School of Pharmacy.


Senior Vice President, Regulatory Affairs and Quality


Shamim Ruff joined Sarepta in January 2013 as our Senior Vice President, Regulatory Affairs and Quality.

Ms. Ruff's experience includes more than twenty-five years in the biopharmaceutical industry, working with a diverse range of therapeutics including small molecules, monoclonal antibodies, oncolytic viruses and oligonucleotides. Her expertise in both domestic and international Regulatory Affairs spans early and late development across multiple therapeutic areas, including Rare Diseases, Oncology, Hematology, Antivirals and Bone Therapy Areas and includes extensive interaction with multiple regulatory agencies globally, including FDA (CDER/CBER/CDRH), EMA/CHMP, Health Canada, and PMDA.

Prior to joining Sarepta, Ms. Ruff served as Vice President, Regulatory Affairs at Sanofi where she was Head of Oncology Regulatory Affairs, responsible for leading Global, European, and CMC Regulatory Affairs teams.  She previously held senior positions at Amgen, Abbott and AstraZeneca where she had global oversight for the development and filings of multiple compounds, some of which had companion diagnostics.  In addition, Ms. Ruff has significant experience leading the preparations for FDA Advisory Committee Meetings.

Ms. Ruff holds a Bachelor’s degree in Chemistry & Biology from the University of Leicester, UK, and a Master’s degree in Analytical Chemistry from the University of Loughborough, UK.  Additionally, she is a Chartered Chemist and Member of the Royal Society of Chemistry (CChem MRSC), and is also an active member of DIA, RAPS and ASCO.


Senior Vice President and Chief Medical Officer


Catherine Stehman-Breen joined Sarepta in April 2017 as our Chief Medical Officer.

Prior to joining Sarepta, Dr. Stehman-Breen served as Vice President, Clinical Development and Regulatory Affairs at Regeneron Pharmaceuticals since 2015, initially as Head, Pain Therapeutic Area, and subsequently as Head, Clinical Project Management and Operations. From 2003 to 2015, she held senior leadership roles at Amgen, including Vice President, Global Development, leading the Neuroscience, Nephrology and Bone Therapeutic Areas.

Dr. Stehman-Breen earned her M.D. from the University of Chicago in 1990. She conducted her residency and fellowship training at the University of Washington, where she also received a Master of Science degree in Epidemiology in 1996. Dr. Stehman-Breen spent six years as a faculty member in the Division of Nephrology at the University of Washington from 1997 to 2003, where her primary responsibilities included managing the Clinical Research Training Program and the development of the Epidemiology and Clinical Trials Research Program. Her research focused on bone and cardiovascular disease in kidney disease patients. Dr. Stehman-Breen was also active in a variety of national programs, including serving as the Chair for USRDS NIDDK External Expert Panel and a reviewer for several journals.